Boothbay Fund Management’s Vera Therapeutics VERA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.33M Buy
100,966
+36,288
+56% +$1.35M 0.06% 396
2026
Q1
$2.6M Buy
64,678
+51,607
+395% +$2.22M 0.03% 522
2025
Q4
$662K Sell
13,071
-4,967
-28% -$176K 0.01% 990
2025
Q3
$524K Sell
18,038
-1,269
-7% -$29.3K 0.01% 1132
2025
Q2
$455K Sell
19,307
-3,693
-16% -$83K 0.01% 935
2025
Q1
$552K Sell
23,000
-1,722
-7% -$55.3K 0.01% 818
2024
Q4
$1.05M Buy
+24,722
New +$1.09M 0.03% 621

Other funds holding VERA

Boothbay Fund Management's VERA Position: Q2 2026 in Review

Boothbay Fund Management increased its Vera Therapeutics (VERA) stake by 56% in Q2 2026, buying an estimated $1.35M and bringing the position to 100,966 shares worth $4.33M. The position accounts for 0.06% of the portfolio, ranked #396.

Boothbay Fund Management first reported a position in VERA in Q4 2024 and has held it in 7 quarters since. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Boothbay Fund Management held 100,966 shares of Vera Therapeutics worth $4.33M as of Q2 2026.
  • Boothbay Fund Management bought 36,288 Vera Therapeutics shares in Q2 2026, an estimated $1.35M.
  • Vera Therapeutics made up 0.06% of Boothbay Fund Management's portfolio in Q2 2026, its #396 holding.
  • Boothbay Fund Management first reported a position in Vera Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.